Choosing Wisely for Thyroid Conditions: Recommendations of the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism

Jose Miguel Dora¹,*
https://orcid.org/0000-0003-3386-713X
Rosa Paula Mello Biscolla²
https://orcid.org/0000-0003-4358-6622
Gustavo Calsdas³
https://orcid.org/0000-0001-9420-5787
Janete Cerutti²
https://orcid.org/0000-0003-0156-8274
Hans Graf⁴
https://orcid.org/0000-0001-8671-1556
Ana O. Hoff⁵
https://orcid.org/0000-0002-7058-6321
Glaucia M. F. S. Mazeto⁶
https://orcid.org/0000-0003-2129-7256
Patrícia Kunzle Ribeiro Magalhães⁷
https://orcid.org/0000-0003-2564-7903
Cleo Otyaviano Mesa Junior⁸
https://orcid.org/0000-0002-9615-137X
Rafael Selbach Scheffel¹
https://orcid.org/0000-0002-8658-309X
Patricia de Fatima dos Santos Teixeira⁹
https://orcid.org/0000-0001-8859-6387
Fernanda Vaisman⁹
https://orcid.org/0000-0002-6835-7108
Donilo Villagelin¹⁰
https://orcid.org/0000-0002-4173-7258
Ana Luiza Maia¹**
https://orcid.org/0000-0002-4186-5532
on behalf of the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism

ABSTRACT

Objective: Choosing Wisely (CW) is an initiative that aims to advance the dialogue between physicians and patients about low-value health interventions. Given that thyroid conditions are frequent in clinical practice, we aimed to develop an evidence-based list of thyroid CW recommendations. Materials and methods: The Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM) named a Task Force to conduct the initiative. The Task Force work was based on an electronic Delphi approach. The 10 recommendations that received the highest scores by the Task Force were submitted for voting by all SBEM associates. The 5 recommendations that received the highest scores by SBEM associates compose our final list. Results: The Task Force was composed of 14 thyroidologists from 10 tertiary-care, teaching-based Brazilian institutions. The brainstorming/ideation phase resulted in 69 recommendations. After the removal of duplicates and recommendations that did not adhere to the initiative's scope, 35 remained. Then the Task Force voted to attribute a grade (0 [lowest agreement] to 10 [highest agreement]) for each recommendation. The 10 recommendations that received the highest scores by the Task Force were submitted to all SBEM associates. A total of 683 associates voted electronically, attributing a grade (0 to 10) for each recommendation. The 5 recommendations that received the highest scores by the SBEM associates compose our final list. Conclusion: A set of recommendations to avoid unnecessary medical tests, treatments, or procedures for thyroid conditions are offered with a transparent methodology. This initiative aims to foster productive interactions between physicians and patients, stimulating shared decision-making.

Keywords: Choosing Wisely; overuse; thyroid; endocrinology
INTRODUCTION

The overuse of low-value interventions is a global problem. A growing body of knowledge highlights that it leads to a waste of precious health care resources and poses patients at risk of harm (1).

Choosing Wisely is a worldwide health care professional-led initiative that aims to advance the dialogue between physicians and patients about low-value health interventions, avoiding wasteful or unnecessary medical tests, treatments, and procedures (2,3).

The Choosing Wisely initiative started in the United States in 2012 led by the American Board of Internal Medicine (ABIM) and is now present in many countries, involving more than one hundred medical associations/societies, hospitals, and universities.

Given that thyroid conditions are widespread and that low-value interventions for these conditions are frequent in clinical practice, we aimed to develop a list of recommendations of measures not to be done when approaching patients with thyroid conditions.

This article aims to summarize the top five recommendations in the list developed by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM) for the Choosing Wisely project.

MATERIALS AND METHODS

In 2017 the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Choosing Wisely Brasil agreed to work towards the development of a list of Choosing Wisely recommendations for thyroid conditions.

The Thyroid Department named a Chair (JMD) and a Co-chair (ALM) for the initiative. Additional members of SBEM, representing thyroid groups from 10 tertiary care, teaching-based Brazilian institutions, were invited to compose the Task Force. Of note, all members of the Task Force were clinical thyroid specialists, not surgeons.

The Task Force work consisted of 3 phases:

1) brainstorming and ideation was conducted electronically through a Delphi approach in which all Task Force members were invited to submit proposals of recommendations;
2) all proposals of recommendations were reviewed, and duplicates removed;
3) the Task Force graded each recommendation on a 0 (lowest agreement) to 10 (highest agreement) scale.

The 10 recommendations that received the highest scores by the Task Force were submitted for voting by e-mail to all SBEM associates, who graded each recommendation on the 0 (lowest agreement) to 10 (highest agreement) scale.

A final list of the 5 recommendations that received the highest scores by the SBEM associates composes the Choosing Wisely – Thyroid SBEM recommendations.

RESULTS

The Task Force was composed of 14 thyroidologists from 10 different Brazilian institutions. The brainstorming and ideation phase resulted in 69 recommendations, thus each member of the Task Force contributed with a median of 3 (min.-max. 1-11) recommendations. After the removal of duplicates and recommendations that did not adhere to the scope of the initiative, 35 recommendations remained. Then the 14 members of the Task Force graded each recommendation. The mean grades for the 35 recommendations ranged from 9.4 ± 1.2 to 6.0 ± 2.3. The 10 recommendations that received the highest scores by the Task Force were then submitted to all SBEM associates by e-mail (Table 1). A total of 683 associates graded each recommendation electronically, attributing a grade (0 to 10) for each recommendation. The grades for the 10 recommendations ranged from 9.8 ± 1.2 to 7.6 ± 2.7, and the 5 recommendations that received the highest scores by the SBEM associates compose our final list of recommendations (Table 2).

The Portuguese version of the 5 recommendations is available as Supplementary Material.

CONCLUSION

In this report, we described the development of the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM) Choosing Wisely initiative list.

A set of recommendations to avoid unnecessary medical tests, treatments, or procedures for thyroid conditions is offered with a transparent methodology. This initiative aims to foster productive interactions between physicians and patients, stimulating shared decision-making and elevating the standards of care for thyroid conditions.
Table 1. Top 10 recommendations of the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM) Task Force

| Recommendations of the Task Force                                                                 | Task Force Grades (n = 14) |
|--------------------------------------------------------------------------------------------------|----------------------------|
| Do not repeat autoantibodies (antithyroperoxidase [anti-TPO] and antithyroglobulin) measurements in the follow-up of patients with Hashimoto’s hypothyroidism who have a previous positive antibody | 9.4 ± 1.2                  |
| Do not order total T3 and/or free T3 measurements in patients without clinical suspicion or diagnosis of hyperthyroidism/ thyrotoxicosis | 9.1 ± 1.6                  |
| Do not order thyroid ultrasound for nodule detection in patients without thyroid anatomic anomalies on clinical examination* | 9.1 ± 1.2                  |
| Do not prescribe triiodothyronine (T3), alone or combined with levothyroxine (T4), for hypothyroidism treatment | 8.6 ± 1.8                  |
| Do not order reverse T3 (rT3) for evaluation of thyroid function                                 | 8.9 ± 1.3                  |
| Do not order thyroglobulin in the initial evaluation of thyroid nodules                           | 8.9 ± 1.9                  |
| Do not order molecular markers in the initial evaluation of patients with thyroid nodules         | 8.6 ± 1.8                  |
| Do not administer high radioactive iodine activities for patients with thyroid carcinoma considered to be of low risk | 8.3 ± 2.4                  |
| Do not maintain suppressive doses of levothyroxine (LT4) in patients with differentiated thyroid carcinoma with excellent response | 8.2 ± 2.3                  |

Grades are expressed as mean ± standard deviation.

* This recommendation does not apply for patients with thyroid cancer predisposing conditions such as multiple endocrine neoplasia type 2 (MEN 2) mutations, patients with two or more family members with thyroid carcinoma and for patients with prior radiation of the neck.

Table 2. Final Choosing Wisely® recommendations and rationale of the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM)

| Recommendation                                                                 | Rationale                                                                                                                                                                                                 |
|-------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Do not order reverse T3 (rT3) for evaluation of thyroid function              | Reverse T3 is derived from the inactivation of T4, which occurs predominantly through type 3 deiodinase activity. It is an inactive hormone, and its serum level does not reflect thyroid function. Thus, its measurement has specific indications (most of them in a research setting) and should not be done to evaluate thyroid function (4-7). |
| Do not prescribe triiodothyronine (T3), alone or combined with levothyroxine (T4), for hypothyroidism treatment | Although the thyroid produces small amounts of T3, there is no evidence that the treatment of hypothyroidism should include T3 seeking improvement of symptoms. T4 is inexpensive, has rapid intestinal absorption and a long half-life (7 days), and allows for single daily intakes and plasma stability of T3 and T4. T4 depends on tissue deiodination for conversion to T3. T3 has a short half-life and requires several daily intakes. Although some experimental animal data suggest that the combination of T4 and T3 may be superior to T4 alone, there is no clear evidence of this effect on humans, so the combination is not routinely recommended (4-6). |
| Do not repeat autoantibodies (antithyroperoxidase [anti-TPO] and antithyroglobulin) measurements in the follow-up of patients with Hashimoto’s hypothyroidism who have a previous positive antibody | Once the autoantibodies (anti-TPO and antithyroglobulin) are positive, the etiology of hypothyroidism is defined, and there is no need to repeat them (4-6). |
| Do not order thyroglobulin in the initial evaluation of thyroid nodules        | Thyroglobulin, a tissue-specific protein, is one of the main parameters in the follow-up of patients with thyroid cancer who have undergone surgery. Serum thyroglobulin levels may increase in various thyroid (benign and malignant) diseases. Thus, serum thyroglobulin measurement does not add information about the nature of thyroid nodules and has no role in thyroid cancer detection (8-10). |
| Do not order molecular markers in the initial evaluation of patients with thyroid nodules | Fine-needle aspiration biopsy (FNAB) is the most accurate and cost-effective method for evaluating thyroid nodules. Molecular markers should only be used if they improve clinical decision-making. The usefulness of a molecular test should be based on strong evidence that the result will add to the decision-making process, thus justifying its incorporation into clinical practice. It is not the case of molecular markers in the diagnosis of thyroid nodules, which have their nature clarified in about 85% of patients undergoing FNAB. The role of molecular markers may be justified in some cases of nodules in which the FNAB did not provide a definitive diagnosis, respecting the particular context of the patient and the health care setting (8-10). |
Acknowledgments: we are grateful to the Thyroid Department (Departamento de Tireoide) and to all members of the Sociedade Brasileira de Endocrinologia e Metabologia, who invested their precious time grading the recommendations for this initiative.

Financial support was received from Fundo de Incentivo à Pesquisa (FIPE/HCPA).

Disclosure: no potential conflict of interest relevant to this article was reported.

**REFERENCES**

1. Brownlee S, Chalkidou K, Doust J, Elshaug AG, Glasziou P, Heath I, et al. Evidence for overuse of medical services around the world. Lancet. 2017;390(10090):156-68.

2. Levinson W, Kallewaard M, Bhatia RS, Wolfson D, Shortt S, Kerr EA; Choosing Wisely International Working Group. 'Choosing Wisely': a growing international campaign. BMJ Qual Saf. 2015;24(2):167-74.

3. Born KB, Levinson W. Choosing Wisely campaigns globally: A shared approach to tackling the problem of overuse in healthcare. J Gen Fam Med. 2018;20(1):9-12.

4. de Carvalho GA, Paz-Filho G, Mesa Junior C, Graf H. Management of endocrine disease: Pitfalls on the replacement therapy for primary and central hypothyroidism in adults. Eur J Endocrinol. 2018;178(6):R231-R244.

5. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al.; American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-751.

6. Brenta G, Vaisman M, Sgarbi JA, Bergoglio LM, Andrade NC, Bravo PP, et al. Clinical practice guidelines for the management of hypothyroidism. Arq Bras Endocrinol Metab. 2013;57(4):265-98.

7. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P Maia AL, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343-421.

8. Rosário PW, Ward LS, Carvalho GA, Graf H, Maciel RMB, Maciel LMZ, et al. Thyroid nodules and differentiated thyroid cancer: update on the Brazilian consensus. Arq Bras Endocrinol Metab. 2013;57(4):240-64.

9. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133.

10. Francis GL, Waguespack SG, Bauer AJ, Angelos P, Benvenga S, Cerutti JM, et al.; American Thyroid Association Guidelines Task Force. Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015;25(7):716-59.
TOP FIVE TIREOIDE SBEM
Recomendações Choosing Wisely Brasil do Departamento de Tireoide da Sociedade Brasileira de Endocrinologia e Metabologia!

1. Não solicite T3 reverso (rT3) na avaliação de função tireoideana.
O T3 reverso é proveniente da inativação de T4, que ocorre predominantemente através enzima deiodinase tipo 3. É um hormônio inativo e a sua dosagem não reflete a função tireoideana. Desta forma, a sua dosagem tem indicações muito específicas (a maioria delas em cenário de pesquisa) e não deve ser feita na avaliação da função tireoideana.

2. Não solicite tireoglobulina sérica na avaliação inicial de nódulos de tireoide.
A tireoglobulina, por ser uma proteína tecido específica, é um dos principais parâmetros no seguimento dos pacientes com câncer de tireoide já submetidos a cirurgia. Os níveis séricos de tireoglobulina podem estar aumentados em diferentes doenças da tireoide (benignas e/ou malignas). Dessa forma, a dosagem da tireoglobulina sérica não adiciona informações sobre a natureza de nódulo de tireoide, e não tem papel no rastreamento de câncer de tireoide.

3. Não utilize marcadores moleculares na avaliação inicial de pacientes com nódulo de tireoide.
A citologia de material de punção aspirativa com agulha fina (PAAF) é o método mais preciso e de baixo custo para avaliar nódulos tireoidianos. Marcadores moleculares só devem ser usados se melhorarem a tomada de decisão clínica. A utilidade de um teste molecular deve ser fundamentada em fortes evidências comprovando que o uso do marcador melhora a tomada de decisão o suficiente para justificar a sua incorporação na prática clínica. Esse não é o cenário de nódulos de tireoide, que tem sua natureza esclarecida em cerca de 85% dos pacientes submetidos a PAAF. O papel dos marcadores moleculares pode ser justificado em alguns casos de nódulos sem diagnóstico definido na PAAF, respeitando o contexto do paciente e do cenário de saúde no qual está inserido.

4. Não utilize triiodotironina (LT3), isolado ou em associação com levotiroxina (LT4), no tratamento de hipotireoidismo.
Apesar de a tiroide produzir pequenas quantidades de T3, não existem evidências de que o tratamento do hipotireoidismo deva incluir T3 procurando melhora dos sintomas. A levotiroxina é barata, tem rápida absorção intestinal e tem uma meia-vida longa (7 dias), o que permite tomadas únicas diárias. Isto promove uma estabilidade plasmática de T3 e T4. A levotiroxina depende da deiodinação tecidual para conversão em triiodotironina. A triiodotironina tem uma meia-vida curta e necessitaria múltiplas tomadas diárias. Apesar de evidências em animais que a combinação de levotiroxina e triiodotironina pode ser superior a levotiroxina isolada, não há evidência clara em humanos disto, por isto a combinação não é recomendada de rotina.

5. Não repita exames de autoanticorpos [antitireoperoxidase (Anti-TPO) e/ou antitireoglobulina] no seguimento de pacientes com hipotireoidismo por tireoidite de Hashimoto com exame anterior positivo.
Uma vez positivos os autoanticorpos [antitireoperoxidase (anti-TPO) e/ou antitireoglobulina], já está definida a etiologia do hipotireoidismo, não havendo qualquer necessidade de repeti-los.

* Metodologia de confecção da seleção: o Departamento de Tireoide da Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) nomeou uma Task Force, composta por 14 especialistas representando diferentes instituições nacionais, para elaborar a lista preliminar de recomendações. Foram elencadas 51 propostas de recomendações, selecionando as 10 melhores ranqueadas por pontuação de relevância clínica. Essas 10 recomendações foram submetidas a votação por todos os associados da SBEM durante os meses de abril e maio de 2017. As 5 recomendações mais votadas pelas sócias da SBEM compuseram as recomendações TOP FIVE Choosing Wisely Brasil do Departamento de Tireoide da SBEM. (Contato: http://www.tireoide.org.br/contato).

Estas recomendações estão disponibilizadas para fins informativos, e não se destinam a substituir a consulta ou avaliação com um profissional médico ou outro profissional da equipe da saúde envolvida na assistência. Pacientes com quaisquer perguntas específicas sobre os itens desta lista ou sua situação individual devem consultar seu médico.